Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Simon Rueckinger"'
Autor:
Leo M. A. Heunks, Frank E.H.P. van Baarle, Lieuwe D. J. Bos, Frederique Paulus, Esther B. Bulle, Simon Rueckinger, Marcus J. Schultz, Matthijs C. Brouwer, Pieter van Paassen, Janneke Horn, Martin Witzenrath, Ingeborg E. van Zeggeren, E. Marleen Kemper, W. Joost Wiersinga, Marcel C. G. van de Poll, Sjoerd A.M.E.G. Timmermans, Rutger Koning, Korinna Pilz, Niels C. Riedemann, Alexander P.J. Vlaar, Diederik van de Beek, Iwan C. C. van der Horst, Matthias Busch, Sanne de Bruin, Liora ter Horst, Ren Feng Guo
Publikováno v:
The Lancet Rheumatology, 2(12), e764-e773. Lancet Publishing Group
The Lancet Rheumatology, 2(12), E764-E773. Lancet Publishing Group
Vlaar, A P J, de Bruin, S, Busch, M, Timmermans, S A M E G, van Zeggeren, I E, Koning, R, Ter Horst, L, Bulle, E B, van Baarle, F E H P, van de Poll, M C G, Kemper, E M, van der Horst, I C C, Schultz, M J, Horn, J, Paulus, F, Bos, L D, Wiersinga, W J, Witzenrath, M, Rueckinger, S, Pilz, K, Brouwer, M C, Guo, R-F, Heunks, L, van Paassen, P, Riedemann, N C & van de Beek, D 2020, ' Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO) : an exploratory, open-label, phase 2 randomised controlled trial ', The Lancet Rheumatology, vol. 2, no. 12, pp. e764-e773 . https://doi.org/10.1016/S2665-9913(20)30341-6
The Lancet Rheumatology
The Lancet Rheumatology, 2(12), E764-E773. Lancet Publishing Group
Vlaar, A P J, de Bruin, S, Busch, M, Timmermans, S A M E G, van Zeggeren, I E, Koning, R, Ter Horst, L, Bulle, E B, van Baarle, F E H P, van de Poll, M C G, Kemper, E M, van der Horst, I C C, Schultz, M J, Horn, J, Paulus, F, Bos, L D, Wiersinga, W J, Witzenrath, M, Rueckinger, S, Pilz, K, Brouwer, M C, Guo, R-F, Heunks, L, van Paassen, P, Riedemann, N C & van de Beek, D 2020, ' Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO) : an exploratory, open-label, phase 2 randomised controlled trial ', The Lancet Rheumatology, vol. 2, no. 12, pp. e764-e773 . https://doi.org/10.1016/S2665-9913(20)30341-6
The Lancet Rheumatology
Background Severe COVID-19 is characterised by inflammation and coagulation in the presence of complement system activation. We aimed to explore the potential benefit and safety of selectively blocking the anaphylatoxin and complement protein C5a wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7a3cabed40314643ba9bb8842abe17e
https://pure.amc.nl/en/publications/antic5a-antibody-ifx1-vilobelimab-treatment-versus-best-supportive-care-for-patients-with-severe-covid19-panamo(1f96aacf-dec4-4976-90c4-4807fe469d43).html
https://pure.amc.nl/en/publications/antic5a-antibody-ifx1-vilobelimab-treatment-versus-best-supportive-care-for-patients-with-severe-covid19-panamo(1f96aacf-dec4-4976-90c4-4807fe469d43).html
Autor:
Alexander P. J. Vlaar, Sanne de Bruin, Matthias Busch, Sjoerd Timmermans, Ingeborg E. van Zeggeren, Rutger Koning, Liora ter Horst, Esther B. Bulle, Frank E.H.P. van Baarle, Marcel C.G. van de Poll, E. Marleen Kemper, Iwan C.C. van der Horst, Marcus J. Schultz, Janneke Horn, Frederique Paulus, Lieuwe D. Bos, W. Joost Wiersinga, Martin Witzenrath, Simon Rueckinger, Korinna Pilz, Matthijs C. Brouwer, Ren-Feng Guo, Leo Heunks, Pieter van Paassen, Niels. C. Riedemann, Diederik van de Beek
Publikováno v:
SSRN Electronic Journal.
Background: Severe coronavirus disease 2019 (Covid-19) is characterized by inflammation and coagulation in the presence of complement activation. Methods: We conducted an explorative phase 2 randomized, open label first part of an adaptive phase 2/3